The Study
Inhibition of RAS-driven signaling and tumorigenesis with a pan-RAS monobody targeting the Switch I/II pocket
This study is like testing a new key to see if it can lock and unlock a specific lock in a lab — it shows the key fits and turns the lock, but we don’t know if it works in real doors, or if it’s safe, or if it works for everyone. We can’t say it cures cancer — just that it might help in a test tube or mouse.
Analysis score
Maximum 90 for a randomized controlled trial.
Where the score came from
Scientists built a tiny protein called JAM20 that sticks to a hidden spot on RAS — a protein that causes many cancers when mutated.
Where does this study sit?
Reviews of RCTs (Meta-analyses)
Max 100Randomized Trials
Max 90Reviews of Cohort Studies
Max 85Cohort Studies
Max 72Reviews of Case-Control Studies
Max 63Case-Control Studies
Max 58Cross-Sectional & Case Series
Max 50Expert Opinion
Max 520 / 100
Quality score
Participants are randomly assigned to treatment or control groups, minimizing bias. The gold standard for testing whether an intervention causes an effect.
Key takeaways
Summary
Based on the study abstract and findings.
- 1Yes — stopping RAS stopped tumors from growing in mice, suggesting this spot could be targeted by future drugs to treat many cancers.
- 2JAM20 blocked RAS in all tested cancer types (KRAS, HRAS, NRAS), stopped tumor growth in mice by 50–70%, and turned off the cancer signal (pERK) in tumors.
Score breakdown, methodology, conflicts of interest, evidence analysis & raw study data
Publication
Journal
Proceedings of the National Academy of Sciences of the United States of America
Year
2022
Authors
Lauren Wallon, I. Khan, K. Teng, A. Koide, M. Zuberi, Jianping Li, G. Ketavarapu, N. Traaseth, J. O’Bryan, S. Koide
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.